Inmune Bio INMB
NASDAQ INMB
$1.95 -0.01 (-0.51%)
At close: Sep 30, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Revenue (2021 - 2025)

Updated

Inmune Bio (INMB) posted Revenue of $50,000 for FY2025, up 257.1% from $14,000 in FY2024.

Analysis

Inmune Bio (INMB) Revenue (2021 - 2025) Analysis & Trends

Since FY2020, Inmune Bio has reported Revenue for 6 years.

  • Annual Revenue shows a five-year compound annual growth rate of 35.4% (FY2020 to FY2025).
  • Annual Revenue has run from a low of $14,000 in FY2024 to a high of $374,000 in FY2022 over five years.
  • Business Quant data shows INMB's Revenue at $14,000 in FY2024 (-91.0%), $155,000 in FY2023 (-58.6%), $374,000 in FY2022 (+106.6%) and $181,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 25.31 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 16.99 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 16.61 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 14.41 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 15.38 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 10.05 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 7.80 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 15.03 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 3.33 Bn
10 Inmune Bio 54.20 Mn -38.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 50,000.00
Mar 31, 2024 14,000.00
Dec 31, 2023 28,000.00
Sep 30, 2023 43,000.00
Jun 30, 2023 46,000.00
Mar 31, 2023 38,000.00
Dec 31, 2022 97,000.00
Sep 30, 2022 98,000.00
Jun 30, 2022 16,000.00
Mar 31, 2022 163,000.00
Dec 31, 2021 163,000.00
Sep 30, 2021 14,000.00
Mar 31, 2021 4,000.00
API Access

Inmune Bio Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=INMB&period=max&api_key=YOUR_API_KEY